Enhancing prognostic power in multiple myeloma using a plasma cell signature derived from single-cell RNA sequencing
Li J, Arsang-Jang S, Cheng Y, Sun F, D’Souza A, Dhakal B, Hari P, Huang Q, Auer P, Li Y, Urrutia R, Zhan F, Shaughnessy J, Janz S, Dong J, Cheng C. Enhancing prognostic power in multiple myeloma using a plasma cell signature derived from single-cell RNA sequencing. Blood Cancer Journal 2024, 14: 38. PMID: 38443358, PMCID: PMC10915134, DOI: 10.1038/s41408-024-01024-8.Peer-Reviewed Original ResearchConceptsInternational Staging SystemPlasma cell malignancyMultiple myelomaCell malignancySpectrum of plasma cell dyscrasiasPlasma cell gene signaturePresence of cytogenetic abnormalitiesRevised ISSHeterogeneous plasma cell malignancyTumor immune microenvironmentPlasma cell dyscrasiaRefining risk stratificationPlasma cell signatureTherapeutic approach to MMShorter overall survivalCytogenetic abnormalitiesOverall survivalR-ISSTP53 mutationsImmune microenvironmentPrognostic effectClinical outcomesStaging systemRisk stratificationPrognostic power